. 2023 Oct 3;14:5962. doi: 10.1038/s41467-023-41231-8

Table 3.

Comparison of estimated MR body-site-specific association between MPB and skin cancer in the UK and Australian population

Cancer outcome by anatomical category	Study (UK)	$N c a s e s_{U K}$	$P_{U K}$	$O R_{U K}$	Study (Aus)	$N c a s e s_{A u s}$	$P_{A u s}$	$O R_{A u s}$	Fixed-effect meta
Cancer outcome by anatomical category	Study (UK)	$N c a s e s_{U K}$	$P_{U K}$	$O R_{U K}$	Study (Aus)	$N c a s e s_{A u s}$	$P_{A u s}$	$O R_{A u s}$	$P_{M E T A}$	$O R_{M E T A}$
Head and neck region
Melanoma (all MPB variant)	UKB	390	0.17	1.20 (0.92 to 1.57)	MIA	537	0.02	1.48 (1.07 to 2.04)	0.01	1.31 (1.07 to 1.61)
Melanoma (MPB exc. outlier)	UKB	390	0.24	1.18 (0.90 to 1.54)	MIA	537	0.10	1.30 (0.95 to 1.76)	0.05	1.23 (1.00 to 1.50)
SCC (all MPB variant)	UKB	1427	0.27	0.92 (0.80 to 1.07)	QSKIN	184	0.94	0.99 (0.65 to 1.49)	0.29	0.93 (0.81 to 1.06)
SCC (MPB exc. outlier)	UKB	1427	0.28	0.92 (0.80 to 1.07)	QSKIN	184	0.52	0.87 (0.57 to 1.32)	0.22	0.92 (0.80 to 1.05)
BCC (all MPB variant)	UKB	4768	0.12	1.07 (0.98 to 1.16)	QSKIN	439	0.12	1.25 (0.94 to 1.67)	0.05	1.08 (1.00 to 1.17)
BCC (MPB exc. outlier)	UKB	4768	0.34	1.11 (0.90 to 1.37)	QSKIN	439	0.36	1.14 (0.86 to 1.51)	0.08	1.08 (0.99 to 1.17)
Upper limb/Arm region
Melanoma (all MPB variant)	UKB	446	0.01	0.72 (0.57 to 0.93)	MIA	280	0.59	1.10 (0.78 to 1.55)	0.08	0.84 (0.68 to 1.02)
Melanoma (MPB exc. outlier)	UKB	446	0.01	0.71 (0.56 to 0.92)	MIA	280	0.72	0.94 (0.68 to 1.31)	0.02	0.79 (0.65 to 0.97)
SCC (all MPB variant)	UKB	284	0.75	1.05 (0.77 to 1.44)	QSKIN	149	0.53	1.16 (0.73 to 1.86)	0.54	1.08 (0.84 to 1.41)
SCC (MPB exc. outlier)	UKB	284	0.91	1.02 (0.74 to 1.40)	QSKIN	149	0.92	1.02 (0.64 to 1.63)	0.88	1.02 (0.78 to 1.32)
BCC (all MPB variant)	UKB	636	0.47	0.93 (0.75 to 1.14)	QSKIN	248	0.49	1.15 (0.78 to 1.68)	0.77	0.97 (0.81 to 1.17)
BCC (MPB exc. outlier)	UKB	636	0.36	0.91 (0.73 to 1.12)	QSKIN	248	0.99	1.00 (0.69 to 1.46)	0.43	0.93 (0.77 to 1.12)
Trunk region
Melanoma (all MPB variant)	UKB	708	0.20	0.89 (0.75 to 1.06)	MIA	1060	0.97	1.00 (0.78 to 1.30)	0.30	0.93 (0.80 to 1.07)
Melanoma (MPB exc. outlier)	UKB	708	0.15	0.88 (0.74 to 1.05)	MIA	1060	0.81	0.97 (0.76 to 1.24)	0.19	0.91 (0.79 to 1.05)
SCC (all MPB variant)	UKB	209	0.74	1.05 (0.77 to 1.43)	QSKIN	23	0.98	0.99 (0.32 to 3.03)	0.76	1.05 (0.78 to 1.41)
SCC (MPB exc. outlier)	UKB	209	0.92	1.02 (0.74 to 1.39)	QSKIN	23	0.71	0.81 (0.26 to 2.51)	1.00	1.00 (0.74 to 1.35)
BCC (all MPB variant)	UKB	1350	0.14	1.11 (0.97 to 1.28)	QSKIN	209	0.90	0.97 (0.66 to 1.45)	0.18	1.10 (0.96 to 1.25)
BCC (MPB exc. outlier)	UKB	1350	0.21	1.10 (0.95 to 1.26)	QSKIN	209	0.73	0.93 (0.63 to 1.39)	0.28	1.08 (0.94 to 1.23)
Lower limb region
Melanoma (all MPB variant)	UKB	239	0.27	0.84 (0.62 to 1.14)	MIA	361	0.55	0.90 (0.65 to 1.26)	0.22	0.87 (0.69 to 1.09)
Melanoma (MPB exc. outlier)	UKB	239	0.33	0.86 (0.63 to 1.17)	MIA	361	0.55	0.93 (0.72 to 1.19)	0.17	0.85 (0.68 to 1.07)
SCC (all MPB variant)	UKB	109	0.60	0.88 (0.56 to 1.39)	QSKIN	102	0.48	1.24 (0.68 to 2.26)	1.00	1.00 (0.70 to 1.43)
SCC (MPB exc. outlier)	UKB	109	0.66	0.90 (0.57 to 1.42)	QSKIN	102	0.93	0.98 (0.55 to 1.75)	0.69	0.93 (0.65 to 1.33)
BCC (all MPB variant)	UKB	269	0.85	1.03 (0.76 to 1.39)	QSKIN	93	0.63	0.87 (0.49 to 1.54)	0.95	0.99 (0.76 to 1.30)
BCC (MPB exc. outlier)	UKB	269	0.90	1.02 (0.75 to 1.39)	QSKIN	93	0.27	0.72 (0.40 to 1.29)	0.69	0.95 (0.72 to 1.24)

For the MR analyses, 96620, 3176 and 1957 controls were used for the UKB, MIA and QSKIN analyses respectively. P-values here were derived from two-tailed z-tests on the MR association estimate (in log(OR)), unadjusted for multiple testing. SNP outliers (for the repeated analyses excluding potentially pleiotropic/heterogenous SNPs) were determined using the MR-PRESSO outlier test at Bonferroni-corrected P value of 0.05. The model MPB exc. outlier refers to the model utilizing MPB variants excluding the four SNP outliers identified by MR-PRESSO.